Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled time : 20:00 save search
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 20:00) - prnewswire.com
LPCN | $5.47 2.82% 2.74% 21K
|
Health Technology
|
| O: -2.52%
H: 6.27%
C: -0.92%
meeting liver presentation results phase 2
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Published: 2023-10-23 (Crawled : 20:00) - biospace.com/
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -1.57%
H: 1.06%
C: 0.36%
enhertu her2 tumors trial phase 2
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
Published: 2023-10-19 (Crawled : 20:00) - globenewswire.com
AEON | $6.54 -3.68% 0.0% 41K
|
|
| O: 1.36%
H: 2.02%
C: -3.36%
abp-450 treatment biopharma topline trial migraine results phase 2
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
Published: 2023-10-09 (Crawled : 20:00) - prnewswire.com
IMUX | $1.28 5.79% 5.47% 280K
|
Health Technology
|
| O: 20.44%
H: 0.26%
C: -28.46%
positive sclerosis trial phase 2
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial
Published: 2023-09-26 (Crawled : 20:00) - globenewswire.com
ADVM | $11.135 -1.89% -1.93% 100K
|
Health Technology
|
| O: 0.0%
H: 1.74%
C: -2.91%
positive protein trial phase 2
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
Published: 2023-09-06 (Crawled : 20:00) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: -1.25%
H: 1.27%
C: -6.84%
candidate vaccine norovirus topline study phase 2
Mineralys Therapeutics Selected for Oral Poster Presentation of Target-HTN Phase 2 Trial Results at 2023 AHA Hypertension Scientific Sessions
Published: 2023-09-05 (Crawled : 20:00) - globenewswire.com
MLYS M | $10.76 -10.33% -11.52% 420K
|
|
| O: -0.08%
H: 1.23%
C: -0.57%
presentation sessions hypertension trial therapeutics results phase 2
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
Published: 2023-08-28 (Crawled : 20:00) - globenewswire.com
GLPG | $28.9 -1.1% -1.11% 140K
|
Health Technology
|
| O: 1.17%
H: 0.24%
C: -1.0%
glpg3667 active lupus start study phase 2
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
Published: 2023-08-10 (Crawled : 20:00) - globenewswire.com
ADVM | $11.135 -1.89% -1.93% 100K
|
Health Technology
|
| O: 4.37%
H: 3.72%
C: -1.05%
trial financial results phase 2
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis
Published: 2023-05-23 (Crawled : 20:00) - globenewswire.com
GLPG | $28.9 -1.1% -1.11% 140K
|
Health Technology
|
| O: 0.83%
H: 0.04%
C: -2.32%
glpg3667 study phase 2
Hepion Pharmaceuticals Schedules Conference Call to Review Topline Results from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
Published: 2023-05-19 (Crawled : 20:00) - globenewswire.com
HEPA | $2.1 -1.41% -1.43% 28K
|
Health Technology
| Email alert
Add to watchlist
liver conference review pharmaceuticals topline trial results phase 2
Alpha Healthcare Acquisition III Merging with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform, in $328M Deal
Published: 2023-01-05 (Crawled : 20:00) - spacfeed.com
ATLXD | $8.1 0
|
n/a
|
| O: -0.18%
H: 8.6%
C: 8.6%
LTUM | $0.0379 33.16% 85K
|
Mining, Quarrying, and Oil and ...
|
| O: 0.0%
H: 5.0%
C: 1.89%
acquisition phase 2
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022
Published: 2022-12-12 (Crawled : 20:00) - biospace.com/
IMGO | $36.01 0.03% 0.0% 0
|
Health Technology
|
| O: 0.01%
H: 0.15%
C: -0.11%
ongoing positive study phase 2
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic ShockOn track for top-line data in April 2022
Published: 2022-03-15 (Crawled : 20:00) - biospace.com/
WINT | News | $0.3399 -15.3% -18.06% 1.8M
|
Health Technology
|
| O: 2.07%
H: 4.17%
C: -0.52%
phase 2 top-line data cardio star enroll topline
The Lancet Publishes Positive Results from Capricor Therapeutics’ Phase 2 Study Evaluating CAP-1002 in Late-Stage Duchenne Muscular Dystrophy
Published: 2022-03-11 (Crawled : 20:00) - biospace.com/
CAPR | $5.055 -8.92% -9.79% 940K
|
Health Technology
|
| O: 5.34%
H: 0.0%
C: 0.0%
cap-1002 phase 2 muscular dystrophy pos therapeutics positive results 100 duchenne positive results lancet
Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome
Published: 2022-02-24 (Crawled : 20:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -4.06%
H: 0.0%
C: 0.0%
RGLS | $2.22 -5.13% -5.41% 200K
|
Health Technology
|
| O: -3.66%
H: 8.0%
C: 6.5%
phase 2 trial therapeutics syndros enroll
Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DMEPhase 2 proof-of-concept study anticipated in 2H 2022
Published: 2022-02-22 (Crawled : 20:00) - biospace.com/
RZLT 4 | $3.305 2.01% 1.97% 280K
|
Technology Services
|
| O: -3.09%
H: 4.9%
C: -3.19%
rz402 phase 2 ces positive results roof
Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
Published: 2022-02-22 (Crawled : 20:00) - biospace.com/
ATHA | $2.07 -1.9% -1.93% 200K
|
Health Technology
|
| O: -1.18%
H: 3.04%
C: 0.54%
ath-1017 alzheimer disease phase 1 phase 2 alzheimer’s alzheimer's disease alzheimer's fosgonimeton
The Majority of Adults with Moderately to Severely Active Crohn's Disease in a Phase 2 Study Achieved Clinical Remission and Corticosteroid-Free Remission Through 48 Weeks with TREMFYA® (guselkumab)
Published: 2022-02-18 (Crawled : 20:00) - biospace.com/
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.73%
H: 0.23%
C: -0.98%
tremfya phase 2 disease active
Phase 1 Study of P-PSMA-101 CAR-T Cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Published: 2022-02-17 (Crawled : 20:00) - poseida.com
PSTX | News | $2.005 -1.72% -1.75% 520K
|
Health Technology
|
| O: -2.24%
H: 15.34%
C: 12.61%
psma-101 prostate cancer state car-t cel phase 1 cancer phase 2 t-cell
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.